GlassScriptPhysician profile
Michael J Carella
NPI 1790737542
$3,473.14
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $284 · 2021: $876 · 2022: $559 · 2023: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,140.09 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $400.96 | 2019-2021 | |
| Lilly USA, LLC | $325.21 | 2019-2023 | Jardiance, Mounjaro, Trulicity |
| Welch Allyn | $191.60 | 2021 | |
| Merck Sharp & Dohme LLC | $166.95 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.04 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $86.39 | 2019-2021 | |
| Amarin Pharma, INC. | $65.45 | 2019-2022 | |
| Embecta Corp. | $64.76 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Xeris Pharmaceuticals, INC. | $61.39 | 2021-2023 | Gvoke Hypopen |
| Shire North American Group INC | $57.96 | 2019 | |
| Abbott Laboratories | $54.52 | 2021-2023 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $54.44 | 2020-2023 | Tepezza |
| Amgen INC. | $52.31 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $51.17 | 2021-2023 | Rexulti |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.